ALNY · Alnylam Pharmaceuticals, Inc.
$228.65
+1.53 (+0.67%)
At close · Aug 14
Market Cap
$30.60B
Shares
133.81M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer (principal executive officer) | $14,867,600 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer (principal financial officer) | $6,863,800 |
| Bryan A. Supran | Executive Vice President, Chief Legal Officer and Secretary | $6,846,350 |
| Pushkal Garg | Executive Vice President, Chief Research and Development Officer | $6,490,500 |
| Tolga Tanguler | Executive Vice President, Chief Commercial Officer | $6,129,020 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer (principal executive officer) | $11,492,970 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer (principal financial officer) | $3,792,780 |
| Pushkal Garg | Executive Vice President, Chief Medical Officer | $2,919,190 |
| Tolga Tanguler | Executive Vice President, Chief Commercial Officer | $2,754,570 |
| Kevin J. Fitzgerald | Executive Vice President, Chief Scientific Officer | $2,673,200 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer (principal executive officer) | $8,895,670 |
| Akshay Vaishnaw | M.D., Ph.D. Former President | $3,317,190 |
| Pushkal Garg | Executive Vice President, Chief Medical Officer | $3,231,090 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer (principal financial officer) | $3,224,360 |
| Tolga Tanguler | Executive Vice President, Chief Commercial Officer | $2,869,710 |
| Kevin J. Fitzgerald | Executive Vice President, Chief Scientific Officer | $2,785,150 |
| Indrani L. Franchini | Executive Vice President, Chief Legal Officer | $1,969,940 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Indrani L. Franchini | Executive Vice President, Chief Legal Officer | $5,408,220 |
| Yvonne Greenstreet | Chief Executive Officer (principal executive officer) | $4,588,810 |
| Akshay Vaishnaw | M.D., Ph.D. Former President | $3,591,620 |
| Pushkal Garg | Executive Vice President, Chief Medical Officer | $2,900,580 |
| Kevin J. Fitzgerald | Executive Vice President, Chief Scientific Officer | $2,445,680 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer (principal financial officer) | $2,421,630 |
| Tolga Tanguler | Executive Vice President, Chief Commercial Officer | $2,352,070 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| John Maraganore | Former ChiefExecutive Officer (principal executive officer) | $10,176,685 |
| Yvonne Greenstreet | MBChB, MBA Chief Executive Officer (principal executive officer) | $8,575,220 |
| Tolga Tanguler | Executive Vice President, Chief Commercial Officer | $6,877,190 |
| Akshay Vaishnaw | M.D., Ph.D. Former President | $5,425,035 |
| Pushkal Garg | Executive Vice President, Chief Medical Officer | $4,047,990 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer (principal financial officer) | $2,798,175 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Barry Greene | Former President | $10,348,318 |
| John Maraganore | Former ChiefExecutive Officer (principal executive officer) | $7,818,164 |
| Yvonne Greenstreet | MBChB, MBA Chief Executive Officer (principal executive officer) | $3,034,001 |
| Akshay Vaishnaw | M.D., Ph.D. President | $2,892,226 |
| Pushkal Garg | Chief Medical Officer and Executive Vice President, Development & Medical Affairs | $2,587,750 |
| Jeffrey Poulton | Executive Vice President, Chief Financial Officer (principal financial officer) | $2,492,968 |
| Laurie B. Keating | Executive Vice President, ChiefLegal Officer and Secretary | $2,434,148 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| John Maraganore | Former ChiefExecutive Officer (principal executive officer) | $7,317,856 |
| Jeffrey Poulton | Executive Vice President, ChiefFinancial Officer (principal financial officer) | $5,877,416 |
| Manmeet S | Soni Former Senior Vice President, Chief Financial Officer (former principal financial officer) | $3,308,932 |
| Yvonne Greenstreet | MBChB, MBA President and Chief OperatingOfficer | $3,250,025 |
| Barry Greene | Former President | $3,118,364 |
| Akshay Vaishnaw | M.D., Ph.D. President,Research and Development | $3,100,952 |
| Laurie B. Keating | Executive Vice President, ChiefLegal Officer and Secretary | $2,421,680 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| John Maraganore | Chief Executive Officer(principal executive officer) | $5,089,269 |
| Barry Greene | Former President | $2,994,383 |
| Yvonne Greenstreet | MBChB, MBA President and Chief OperatingOfficer | $2,682,755 |
| Akshay Vaishnaw | M.D., Ph.D. President,Research and Development | $2,619,671 |
| Laurie B. Keating | Executive Vice President, ChiefLegal Officer and Secretary | $1,614,018 |
| Manmeet S | Soni Former Senior Vice President, Chief Financial Officer (former principal financial officer) | $1,363,761 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Manmeet S | Soni Former Senior Vice President, Chief Financial Officer (former principal financial officer) | $4,481,700 |
| John Maraganore | Ph.D. Chief ExecutiveOfficer (principal executive officer) | $1,417,394 |
| Yvonne Greenstreet | MBChB, MBA ChiefOperating Officer | $984,674 |
| Barry Greene | President | $944,145 |
| Akshay Vaishnaw | M.D., Ph.D. President, Researchand Development | $915,218 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Benjamin F. Cravatt, Ph.D. | Class III director | Appointed | 2026-05-27 |
| Stuart A. Arbuckle | non-employee director | Appointed | 2025-12-03 |
| Carolyn Bertozzi, Ph.D. | Board of Directors | Resigned | 2025-12-03 |
| Michael W. Bonney | Board of Directors | Resigned | 2025-12-03 |
| Phillip A. Sharp | Board of Directors | Retired | 2025-03-05 |
| Marsha H. Fanucci | Board | Resigned | 2023-09-28 |
| Akshay K. Vaishnaw, M.D., Ph.D. | Chief Innovation Officer | Appointed | 2023-08-03 |
| Akshay K. Vaishnaw, M.D., Ph.D. | President | Resigned | 2023-08-03 |
| Peter N. Kellogg | Class II director | Appointed | 2023-03-08 |
| Amy W. Schulman | Chair of the Board | Appointed | 2023-01-06 |
| Carolyn R. Bertozzi | Class III director | Appointed | 2023-01-06 |
| Dr. Elliott Sigal | Class I director | Appointed | 2022-08-24 |
| Steven M. Paul, M.D. | member of the Board of Directors | Resigned | 2022-04-05 |
Key facts
CIK
1178670
CUSIP
02043Q107
13F (30d)
739 filings
705 filers
Visit website
Investor relations